The first multidisciplinary consensus recommendations for palliative and supportive care in Creutzfeldt-Jakob disease and related prion disorders were published in Age and Ageing on 2 July 2026 (volume 55, issue 7, article afag206). The document was written by a 35-author panel of prion physician, nurse and research specialists, palliative care doctors, psychiatrists, a general practitioner, a clinical neuropsychologist and a lived-experience representative, with Simon Mead of the MRC Prion Unit at UCL as corresponding author. The authors state that involving the lived-experience representative was integral to keeping the recommendations patient-focused, and that a section on support for families and professionals was included to cover the impact on caregivers and the resources open to them. Much of the guidance, the authors write, can also be applied to other rapidly progressive dementias.
The recommendations are consensus-based, not trial-based. The panel held an initial workshop to map the available evidence and decide which symptom clusters to prioritise; individual authors then reviewed the relevant literature and drafted subsections, which were refined iteratively. A PubMed literature search was run on 26 January 2026. The authors are explicit that, because prion disease is rare, the evidence base for symptomatic management is very limited, and that there are no cures or disease-modifying treatments, leaving supportive care and symptom management as the mainstay. The guidance is aimed at healthcare professionals, and the authors note it may also help patients and families argue for good care.
The scale of the caregiving problem has been set out in two other recent studies. A systematic review by Williams and colleagues, published in BMC Palliative Care on 27 April 2026 (volume 25, article 169), counted 109 distinct symptoms reported across the quantitative literature on sporadic, iatrogenic and variant CJD, 374 symptom reports in total, with myoclonus the most prevalent at 37.9 per cent within its category; that review records a median survival in sporadic CJD of five months from symptom onset, with a range from weeks to as long as ten years. A retrospective review of Mayo Clinic records from January 2012 to August 2023, published in Neurology on 2 September 2025, found that of 172 patients with symptomatic prion disease, 165 (94.8 per cent) had at least one symptom or sign amenable to supportive care, while 113 (65.7 per cent) accessed palliative care resources.
The Age and Ageing paper also sets United Kingdom practice alongside Japan's, noting that Japan has national prion disease clinical practice guidance, with an updated guideline scheduled for publication in 2026, and that the sharpest divergence concerns assisted nutrition when swallowing becomes unsafe, where Japanese decisions are strongly shaped by family preferences and social norms. On bereavement, the authors point families and clinicians to national CJD specialists before and after a death, alongside GPs, local palliative care teams, hospital bereavement services and third sector organisations.